AZD1480: Difference between revisions
Jump to navigation
Jump to search
imported>Kevin No edit summary |
imported>Kevin No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Description== | ==Description== | ||
Inhibits the Jak Stat pathway. AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1. | Inhibits the Jak Stat pathway. AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1. | ||
[[File:azd1480.gif]] | [[File:azd1480.gif|frame|right|Structure of AZD1479, photo from Selleck Chemical]] | ||
**Genes Affected | **Genes Affected | ||
| Line 8: | Line 8: | ||
==Suppliers== | ==Suppliers== | ||
[http://www.selleckchem.com/products/azd1480.html Selleck Chemicals] | *[https://pubchem.ncbi.nlm.nih.gov/compound/16659841 PubChem] | ||
[http://www.scbt.com/datasheet-364735-azd1480.html Santa Cruz ] | *[http://www.selleckchem.com/products/azd1480.html Selleck Chemicals] | ||
*[http://www.scbt.com/datasheet-364735-azd1480.html Santa Cruz ] | |||
==Usage Notes== | ==Usage Notes== | ||
| Line 15: | Line 16: | ||
*[http://www.xenbase.org/literature/article.do?method=display&articleId=50713 Hyakutake et al., 2015] | *[http://www.xenbase.org/literature/article.do?method=display&articleId=50713 Hyakutake et al., 2015] | ||
*[http://www.xenbase.org/literature/article.do?method=display&articleId=42239 Bergmann et al., 2010] | *[http://www.xenbase.org/literature/article.do?method=display&articleId=42239 Bergmann et al., 2010] | ||
* | |||
*[[Small Molecules for Xenopus Research|Back To Small Molecules Home Page]] | |||
Latest revision as of 12:28, 2 June 2015
Description
Inhibits the Jak Stat pathway. AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.
